RxDoctor Payments Data

Paul Krabbenhoft, MD

Physical Medicine & Rehabilitation · Lincoln, NENPI 1306955661

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 33.2% of the total. 2025 is the largest year on record at $511, 4.4 times the $117 reported in 2019.

$1,353in general payments, 2019–2025

Across 60 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$449
  • Coloplast$169
  • Ipsen Biopharmaceuticals, Inc$160
  • Merz Pharmaceuticals, LLC$134
  • Viiv Healthcare Company$93
  • Dynasplint Systems Inc.$51
  • plus $298 from 10 others

What the payments were for

  • Food & beverage$1,353100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,353 in reported general payments places this provider in the 80th percentile of 57 physical medicine & rehabilitation providers in Nebraska.

See all physical medicine & rehabilitation providers in Nebraska

Medicare billing

Part B allowed, 2024
$41,590
Medicare patients
74
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron49$32,115
GemtesaVibegron16$15,013
Dantrolene Sodium53$9,208
Baclofen101$6,929
EliquisApixaban14$6,900
Gabapentin61$2,838
Methenamine Hippurate19$1,509
Pregabalin22$1,027
Oxybutynin Chloride17$681
Tizanidine Hcl22$659
Celecoxib20$388
Solifenacin Succinate15$311
Oxybutynin Chloride ErOxybutynin Chloride15$214
Diazepam22$211
Amitriptyline Hcl14$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$44$15,01316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 57 physical medicine & rehabilitation providers in Nebraska.

Other physical medicine & rehabilitation in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →